SARS is to sell shares in a BVI company, allegedly transferred to hide large amount of revenues
Businessman Dave King failed to postpone a case brought by the South African Revenue Service (SARS), for the right to sell shares in a British Virgin Island company. SARS is trying to receive back taxes allegedly owed by King, and to sell the BVI company shares that are said to be transferred to hide King’s wealth.
It is the last episode in a seven-year war between SARS and King, for tax debts owed by King and his offshore trust Ben Nevis Holdings (also registered in BVI). SARS alleges that Ben Nevis in 2002 transferred all of its South African assets to the offshore company Metlika Trading (BVI), to disturb authorities from looking into BVI trust’s assets. BVI-registered Metlika is the major shareholder in South African companies that own wine farms, game farms and King’s homes.
It is claimed by SARS that Ben Nevis Holdings owes R1,4 billion in debts and penalties, for non-declaring income from the sale of shares in King’s company. SARS says that the money made by Ben Nevis from the sale of shares from Specialised Outsourcing of this company was revenue, so Ben Nevis and Kings are liable to taxes on it. King argues the proceeds have capital nature, so they are not taxable in South Africa.
It was ruled by the court that the case against Ben Nevis and King are to be separated, and the King case would be heard at a later date. This is because King is also facing a criminal case, and any testimony he gives in the tax trial might incriminate him. Also, by the order of the court, King must pay the costs of the two-week application.
King is personally believed to owe SARS R900mln for false declarations in his tax returns for the years 1990-2001. In March of this year, King lost a bid against the UK Fraud Office, to retain all his foreign assets, which probably make the most substantial part of his wealth. It was ruled by the UK court that the restraint order remained in place, but limited it to the UK, Guernsey and Scotland, not extending it worldwide as SARS had hoped.